Sol-Gel Technologies Return on Equity

Sol-Gel Technologies (SLGL) currently reports a ROE of -33.97%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Sol-Gel Technologies's ROE history and peer comparisons.

Sol-Gel Technologies's ROE of -33.97% is higher than the Healthcare sector average of -75.84%. That is roughly 55.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sol-Gel Technologies's current -33.97% should be judged against Healthcare norms (sector average: -75.84%) and against SLGL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -33.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Sol-Gel Technologies, and consider following SLGL for alerts when major investors trade the stock.

Sol-Gel Technologies is classified in the Healthcare sector. On ROE, it currently shows -33.97% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SLGL with unrelated industries.